StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$2.85−0.15 (-5.15%)

Close on Nov 18, 2026Market cap $304.54MP/E –Yield –

Relmada Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Relmada Therapeutics's free cash flow for the twelve months ending Jun 30, 2018 was -$6.01M. For fiscal 2018 it was -$6.01M.

Annual free cash flow

PeriodPeriod endValueChange
FY2018Jun 30, 2018-$6.01M–
FY2017Jun 30, 2017-$6.52M–
FY2016Jun 30, 2016-$13.71M–
FY2013Dec 31, 2013-$2.25M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2018CQ2 2018Jun 30, 2018-$2.28M–
Q3 FY2018CQ1 2018Mar 31, 2018-$1.63M–
Q2 FY2018CQ4 2017Dec 31, 2017-$1.13M–
Q1 FY2018CQ3 2017Sep 30, 2017-$981.64K–
Q4 FY2017CQ2 2017Jun 30, 2017-$1.02M–
Q3 FY2017CQ1 2017Mar 31, 2017-$1.88M–
Q2 FY2017CQ4 2016Dec 31, 2016-$1.45M–
Q1 FY2017CQ3 2016Sep 30, 2016-$2.17M–
Q4 FY2016CQ2 2016Jun 30, 2016-$2.85M–
Q3 FY2016CQ1 2016Mar 31, 2016-$3.69M–
Q2 FY2016CQ4 2015Dec 31, 2015-$3.95M–
Q1 FY2016CQ3 2015Sep 30, 2015-$3.22M–
Q3 FY2013CQ3 2013Sep 30, 2013-$409.46K–

More Relmada Therapeutics figures

See a number that looks wrong?